Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR68 | Q15743 | 2/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1520714 | 0.84 | HSD17B10 (0.55) | GPR68ADORA2AHTR2BBACE1HSD17B10 | |
| SCHEMBL10703976 | 0.80 | HSD17B10 (0.50) | GPR68ADORA2AHTR2BHSD17B10IDO1 | |
| SCHEMBL22499482 | 0.76 | ALDH1A1 (0.35) | GPR68ADORA2AHTR2BHPGDLMNA | |
| SCHEMBL22499479 | 0.76 | ALDH1A1 (0.35) | GPR68ADORA2AHTR2BHPGDLMNA | |
| SCHEMBL3853354 | 0.76 | BACE1 (0.51) | BACE1HSD17B10IDO1HPGDALDH1A1 | |
| SCHEMBL4529804 | 0.76 | BACE1 (0.51) | GPR68BACE1HSD17B10IDO1HPGD | |
| SCHEMBL17595576 | 0.74 | MAPT (0.48) | HSD17B10HPGDLMNAGAAL3MBTL1 | |
| SCHEMBL31006473 | 0.74 | IDO1 (0.69) | BACE1HSD17B10IDO1HPGDALDH1A1 | |
| SCHEMBL6541555 | 0.74 | IDO1 (0.69) | BACE1HSD17B10IDO1HPGDALDH1A1 | |
| SCHEMBL3159306 | 0.74 | HSD17B10 (0.52) | BACE1HSD17B10IDO1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920075-B2 | Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920075-B2 | Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920075-B2 | Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170247396-A1 | TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247396-A1 | TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247396-A1 | TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2017-08-31 | — | — | US | disclosed |
| EP-3191485-A1 | TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | Bristol-Myers Squibb Company (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040417-A1 | TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247396-A1 | TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | GPR68 2543/4885ADORA2A 2673/4885HTR2B 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.